Antigen-driven TCR signaling in the epidermis during CD8+ TRM differentiation results in a lower TGFβ requirement for persistence and increased proliferative capacity that together enhance epidermal ...
Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback